Journal News

ASBMB journals will be fully open access in 2021

ASBMB Today Staff
By ASBMB Today Staff
May 11, 2020

Earlier today, the American Society for Biochemistry and Molecular Biology announced that its three peer-reviewed journals will become, as of January, open access. You can read the announcement in full below. The society also created a page with frequently asked questions.


As elected, editorial and administrative leaders of the American Society for Biochemistry and Molecular Biology, we are pleased to announce that the society’s three highly regarded journals — Journal of Biological Chemistry, Molecular & Cellular Proteomics and Journal of Lipid Researchwill be fully open access beginning in January 2021.

The ASBMB exists to meet the needs and respond to the demands of its members, and our members, in line with the broader scientific community, have called for immediate and free public access to research published in ASBMB journals in order to reduce barriers to scientific knowledge and accelerate discoveries.

ASBMB journals have for years made accepted manuscripts immediately available for free as Papers in Press and have embargoed the final redacted versions of articles for subscribers for only a single year. In addition, authors have had the option to pay an additional fee for immediate open access of the final version of a paper or upload the accepted version for free to a public repository. As of January, the final versions of all articles will be immediately available to everyone, qualifying ASBMB journals as “gold” open access. This is important because an increasing number of funders of biomedical research are requiring its grantees to publish in only “gold” journals.

Our decision-making process was careful and consultative. During our months-long deliberations, we had to balance what is best for science and scientists with what is sustainable for a nonprofit organization. Ultimately, we determined that the ASBMB cannot achieve its goal of full open access alone, so we made the strategic decision to enter into an agreement with the commercial publisher Elsevier, which has experience transitioning subscription journals to full open access and the requisite technical expertise and infrastructure.

We want to emphasize that this agreement will not change the peer-review process at any of our journals. JBC, MCP and JLR remain committed to rigorous, fast and fair review — by active scientists.

We are happy to report, also, that the agreement will smooth the submission process for authors and reduce the cost of open-access publishing — for both members and nonmembers alike. It also will make our journals easier to read on mobile devices, discoverable on the platform ScienceDirect and, generally speaking, more nimble technologically.

Transitioning from a subscription model to an open-access model is complicated, but we know this is the right decision for the ASBMB. Throughout our deliberations, we kept focused on our goal: to make the high-quality papers we publish immediately and permanently available for everyone to read, download, copy and distribute.

We will share more information on the transition in the months to come. In the meantime, we hope that you will reach out to us if you have any questions or concerns.

Sincerely,

Gerald Hart (President, ASBMB)
Joan Conaway (Treasurer, ASBMB)
Sandra Weller (Chair, ASBMB Publications Committee)
Toni Antalis (President-elect, ASBMB)
Lila M. Gierasch (Editor-in-Chief, Journal of Biological Chemistry)
Alma Burlingame (Editor-in-Chief, Molecular & Cellular Proteomics)
Kerry-Anne Rye and Nicholas O. Davidson (Co-Editors, Journal of Lipid Research)
Barbara Gordon (Executive Director, ASBMB)
Nancy Rodnan (Senior Director, ASBMB Publications)
Steve Miller (Deputy Executive Director and Chief Financial Officer, ASBMB)

ASBMB Today Staff
ASBMB Today Staff

This article was written by a member or members of the ASBMB Today staff.

Join the ASBMB Today mailing list

Sign up to get updates on articles, interviews and events.

Latest in Science

Science highlights or most popular articles

The NIH is turning the human reference genome into a pangenome
News

The NIH is turning the human reference genome into a pangenome

November 26, 2020

In 2000, the human genome was announced as completed. But it was filled with gaps, and did not represent humanity’s genetic diversity. Read and watch a short film about recent updates.

From the journals: MCP
Journal News

From the journals: MCP

November 25, 2020

A destructive disease can lurk in a citrus plant’s vascular system. Misfolded proteins offer a key to inflammation in liver disease. And proteomic studies provide clues about signaling linked to neurological disorders.

Targeting two-faced nuclear receptors to fight cancer
News

Targeting two-faced nuclear receptors to fight cancer

November 24, 2020

For small-molecule cancer drugs, context is everything. Drugs that ameliorate cancer in some tissues may increase the cancer risk in others. Researcher Stephen Safe has turned this challenge into an opportunity.

 Government-funded scientists laid the groundwork for billion-dollar vaccines
News

Government-funded scientists laid the groundwork for billion-dollar vaccines

November 22, 2020

Basic research conducted at the NIH, Defense Department and federally funded academic laboratories has been essential to rapid development of vaccines in response to COVID-19.

Knocking out drug side effects with supercomputing
News

Knocking out drug side effects with supercomputing

November 21, 2020

A team from Stanford University used the world's fastest supercomputer to simulate how drug molecules might alter the arrangement of G protein-coupled receptors to deliver beneficial effects without side effects.

From the journals: JLR
Journal News

From the journals: JLR

November 19, 2020

A master regulator governing color production in yeast and fungi, a novel cholesterol trafficking pathway in blood, and a lipid metabolite that regulates neuronal firing.